ARIAD Pharmaceuticals
Wikipedia on Answers.com:
Top
ARIAD Pharmaceuticals
 |
|
| Type | Public |
|---|---|
| Traded as | NASDAQ: ARIA |
| Industry | Pharmaceuticals, biotechnology |
| Founded | 1991 |
| Headquarters | Cambridge, MA, United States |
| Key people | Harvey Berger, Chairman & CEO Timothy P. Clackson, President of Research and Development and Chief Scientific Officer |
| Products | Ridaforolimus (Under development) Ponatinib (Under development) AP26113 (Under development) |
| Revenue |  US$178.98M (FY 2010)[1] |
| Operating income | US$104.90M (FY 2010)[2] |
| Net income | US$85.25M (FY 2010)[3] |
| Total assets |  US$50.4M (FY 2010)[4] |
| Employees | 125 (2011) |
| Website | www.ariad.com |
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is a small pharmaceutical company working on cancer drugs. The company is located in Cambridge, Massachusetts. It was established in 1991 by Larry Bock, David Blech and Harvery Berger. It has strong partnerships with Merck.
|
Contents
|
Products
Products under development
- Ponatinib
- Ridaforolimus (formerly Deforolimus, partnered with Merck)
- AP26113
See also
References
External links
‹thc/cht
›
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article ARIAD Pharmaceuticals.
Read more